|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[±¹³»Á¦¾à»ç] PV (2³â ÀÌ»ó)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
06.23 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[À¯¸íÁ¦¾à»ç] PV / 2³âÀÌ»ó~12³â¹Ì¸¸ /¼Ãʱٹ«
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
06.27 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
´ëÇüÁ¦¾à»ç PV/MI(´ë¸®~°úÀå±Þ)
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
05.03 |
|
|
¸ÇÅ佺ÆÄ¿ö |
[À¯¸í¹ÙÀÌ¿À-PV] ¾à¹°°¨½Ã/PMS/SDEA/´ë¸®±Þ
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
|
05.07 |
|
|
ÆÊÄ¿³ØÆà |
[½Å¾à°³¹ß»ç] ºñÀÓ»ó´ã´ç PL
°æ±â ¼ö¿ø½Ã ¿µÅ뱸 | ´ëÇпø(¼®»ç) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
05.31 |
04.16 |
|
|
ÆÊÄ¿³ØÆà |
[½Å¾à°³¹ß»ç] ºñÀÓ»ó´ã´ç PL
°æ±â ¼ö¿ø½Ã ¿µÅ뱸 | ´ëÇпø(¼®»ç) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
05.31 |
04.02 |
|
|
JN Partners |
[¿Ü±¹°èÁ¦¾àȸ»ç] PV¾à»ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
02.21 |
|
|
À̳ë¼Ä¡ |
±Û·Î¹úÁ¦¾à¹ÙÀÌ¿À PV [Pharmacovigilance]
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
06.15 |
|
|
HRKorea |
°³¹ßº»ºÎ³» PVÆÀ : PV SOP/°¡À̵å¶óÀÎ µî °ü¸®¹®¼ Á¦/°³Á¤
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
12.22 |
|
|
Ä¿¸®¾îÄɾî |
´Ù±¹ÀûÁ¦¾àȸ»ç CSO (Clinical Safety Officer)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
09.27 |
|
|
JYpartners |
[[µ¶ÀÏ°è Åõ¼® Àü¹®±â¾÷]]PV manager ½Å±Ôä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
12.03 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[±¹³»Á¦¾à»ç] PV (2³â ÀÌ»ó)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
07.01 |
|
|
JYpartners |
[[¾à»ç, ÇѾà»ç Çʼö]] CRA 2³â ÀÌ»ó °æ·ÂÀÚ OK
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
05.06 |
|
|
JYpartners |
[[µ¶ÀÏ°è Åõ¼® Àü¹®±â¾÷]]PV manager ½Å±Ôä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
12.03 |
|
|
HRKorea |
Pharmacovigilance Specialist
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
05.18 |
|